|
25.01.2005 13:03:00
|
Applied Biosystems Completes Staffing of Divisional Leadership Positio
Applied Biosystems Completes Staffing of Divisional Leadership Positions; William V. Murray Appointed Division President, Molecular Biology Molecular Biology Division Senior Management Team Completed
Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, today announced it has completed staffing the most senior management positions in its Molecular Biology Division, the Group's largest division.
William V. Murray has been appointed Division President, Molecular Biology. Presidents of the three other Applied Biosystems Divisions have been in place since last summer. They are Laura C. Lauman, Proteomics and Small Molecules; Mark Stevenson, Applied Markets; and Michael G. Schneider, Services and Solutions.
"Bill's success in providing leadership and general management to large, complex and global businesses while a senior executive at Medtronic makes him extremely well suited for taking the Molecular Biology Division to the next level of performance," said Catherine M. Burzik, President, Applied Biosystems.
"I am pleased that our senior leadership team is now in place. Our new divisional structure, implemented over the past six months, is beginning to gain traction both in terms of assuring clearer alignment with business needs of our customers, as well as enabling improved internal focus on operational efficiency," she added. "We expect these changes can foster closer relationships with customers, drive faster, new product development and market penetration, and create greater accountability."
Molecular Biology is Applied Biosystems' largest division and represents core products in its sequencing, PCR, and gene expression platforms and technologies. Mr. Murray will be responsible for all aspects of the Molecular Biology Division including: Strategic planning and business development, R&D, product management, marketing, and program management. He will have direct responsibility for sales in North America and shared responsibility, with the regional vice presidents, for sales of Molecular Biology products outside North America.
Mr. Murray brings more than 20 years of engineering, manufacturing, and executive management experience to his new position. Most recently, he was the Group President, Respiratory Technologies, for VIASYS Healthcare, Inc. (NYSE:VAS). Previously, Mr. Murray was at Medtronic, Inc. (NYSE: MDT) for 17 years, where he held a series of executive positions including Vice President and General Manager of the global pacemaker business; and Vice President, Business Operations, of the Arrhythmia Management Business. In those roles, he managed organizations with more than 5,000 employees.
Additionally, within the Molecular Biology Division, Carl W. Hull has been named Vice President and General Manager, Real-Time PCR Systems and Microarrays; Stephen J. Kondor has been named Vice President and General Manager, Genetic Analysis; and Peter M. Dansky has been named Senior Director and General Manager, Core PCR and DNA Synthesis.
Mr. Hull, Mr. Kondor, and Mr. Dansky are each responsible for overseeing the business strategy, portfolio and product line management, marketing strategies, and execution of new product development in their product and technology areas.
Mr. Hull has responsibility for driving the continued commercial success of the real-time PCR instrumentation and reagent product lines and maximizing the market potential of the Applied Biosystems' Expression Array System. Mr. Hull's most recent role was Chief Executive Officer for Applied Imaging Corp. (NASDAQ Small Cap: AICXE), a genetics and pathology instrumentation company. Prior to that position, Mr. Hull was Vice President of Marketing and Business Development at Ventana Medical Systems, Inc. (NASDAQ: VMSI), a cancer diagnostics company. Mr. Hull spent over 14 years at Abbott Laboratories (NYSE: ABT) in a variety of product management, marketing, sales, and general management positions.
Mr. Kondor is responsible for Applied Biosystems' industry-leading capillary electrophoresis instruments and DNA sequencing reagents, as well as product lines in sample preparation, genetic analysis software, sequencing and resequencing applications, and genotyping applications and software. Mr. Kondor has more than 20 years of experience in the sales, marketing, and general management of life sciences. Recently, he was Vice President and General Manager for Fisher Scientific (NYSE: FSH), with accountability for its Diagnostic Business Unit. Prior to that, he held senior executive roles with several medical device companies, including Becton, Dickinson and Company (NYSE: BDX) and Abbott Diagnostics, where his positions included Worldwide Commercial Director for the Hematology Business Unit and General Manager for Immunoassay Systems.
Mr. Dansky is responsible for leading the efforts in Applied Biosystems' core PCR and DNA synthesis groups. Mr. Dansky brings more than 20 years of marketing, product development, and sales experience from a variety of life science companies, including Affymetrix, Inc. (Nasdaq: AFFX) and Millipore Corporation (NYSE: MIL). Most recently, he was Vice President, Marketing, for Arcturus Bioscience where he led the commercialization of microgenomics products for life science research and clinical diagnostics markets.
Laura C. Lauman, Mark Stevenson, and Michael G. Schneider assumed leadership of their divisions after they were created in July 2004. Like Mr. Murray, each is responsible for defining and executing strategic direction and overall management of their division.
Ms. Lauman has held progressively more responsible positions managing Applied Biosystems mass spectrometry-related product lines since joining the company in 1988. In addition to her role as Division President, Proteomics and Small Molecules, she is responsible for the management and is a board member of the Applied Biosystems/MDS SCIEX Joint Venture.
Prior to his current position, Mr. Stevenson was President and General Manager of Applied Biosystems Japan Ltd, responsible for directing the sales, service and support efforts in Japan. Previously, Mr. Stevenson had similar responsibility for Applied Biosystems' genomics and informatics business throughout Europe. He joined Applied Biosystems in 1998. His Applied Markets division produces reagent kits for human identification and market opportunities in biosecurity, food/agriculture, and environment.
Mr. Schneider joined Applied Biosystems in 2004 as Vice President, Worldwide Service. His career spans more than 20 years at Eastman Kodak, and included service as Director of Operations and Service Strategy and Director of Worldwide Service Operations for the Health Imaging Division. At Kodak, Mr. Schneider was responsible for creating and implementing worldwide service strategies to enhance the company's overall service offerings. He has similar responsibilities at Applied Biosystems.
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2004. The Celera Genomics Group (NYSE:CRA) is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. It is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/.
--30--WG/sf*
Business Editors/Health/Medical Writers
BIOWIRE2K
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 25, 2005--
Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, today announced it has completed staffing the most senior management positions in its Molecular Biology Division, the Group's largest division.
William V. Murray has been appointed Division President, Molecular Biology. Presidents of the three other Applied Biosystems Divisions have been in place since last summer. They are Laura C. Lauman, Proteomics and Small Molecules; Mark Stevenson, Applied Markets; and Michael G. Schneider, Services and Solutions.
"Bill's success in providing leadership and general management to large, complex and global businesses while a senior executive at Medtronic makes him extremely well suited for taking the Molecular Biology Division to the next level of performance," said Catherine M. Burzik, President, Applied Biosystems.
"I am pleased that our senior leadership team is now in place. Our new divisional structure, implemented over the past six months, is beginning to gain traction both in terms of assuring clearer alignment with business needs of our customers, as well as enabling improved internal focus on operational efficiency," she added. "We expect these changes can foster closer relationships with customers, drive faster, new product development and market penetration, and create greater accountability."
Molecular Biology is Applied Biosystems' largest division and represents core products in its sequencing, PCR, and gene expression platforms and technologies. Mr. Murray will be responsible for all aspects of the Molecular Biology Division including: Strategic planning and business development, R&D, product management, marketing, and program management. He will have direct responsibility for sales in North America and shared responsibility, with the regional vice presidents, for sales of Molecular Biology products outside North America.
Mr. Murray brings more than 20 years of engineering, manufacturing, and executive management experience to his new position. Most recently, he was the Group President, Respiratory Technologies, for VIASYS Healthcare, Inc. (NYSE:VAS). Previously, Mr. Murray was at Medtronic, Inc. (NYSE: MDT) for 17 years, where he held a series of executive positions including Vice President and General Manager of the global pacemaker business; and Vice President, Business Operations, of the Arrhythmia Management Business. In those roles, he managed organizations with more than 5,000 employees.
Additionally, within the Molecular Biology Division, Carl W. Hull has been named Vice President and General Manager, Real-Time PCR Systems and Microarrays; Stephen J. Kondor has been named Vice President and General Manager, Genetic Analysis; and Peter M. Dansky has been named Senior Director and General Manager, Core PCR and DNA Synthesis.
Mr. Hull, Mr. Kondor, and Mr. Dansky are each responsible for overseeing the business strategy, portfolio and product line management, marketing strategies, and execution of new product development in their product and technology areas.
Mr. Hull has responsibility for driving the continued commercial success of the real-time PCR instrumentation and reagent product lines and maximizing the market potential of the Applied Biosystems' Expression Array System. Mr. Hull's most recent role was Chief Executive Officer for Applied Imaging Corp. (NASDAQ Small Cap: AICXE), a genetics and pathology instrumentation company. Prior to that position, Mr. Hull was Vice President of Marketing and Business Development at Ventana Medical Systems, Inc. (NASDAQ: VMSI), a cancer diagnostics company. Mr. Hull spent over 14 years at Abbott Laboratories (NYSE: ABT) in a variety of product management, marketing, sales, and general management positions.
Mr. Kondor is responsible for Applied Biosystems' industry-leading capillary electrophoresis instruments and DNA sequencing reagents, as well as product lines in sample preparation, genetic analysis software, sequencing and resequencing applications, and genotyping applications and software. Mr. Kondor has more than 20 years of experience in the sales, marketing, and general management of life sciences. Recently, he was Vice President and General Manager for Fisher Scientific (NYSE: FSH), with accountability for its Diagnostic Business Unit. Prior to that, he held senior executive roles with several medical device companies, including Becton, Dickinson and Company (NYSE: BDX) and Abbott Diagnostics, where his positions included Worldwide Commercial Director for the Hematology Business Unit and General Manager for Immunoassay Systems.
Mr. Dansky is responsible for leading the efforts in Applied Biosystems' core PCR and DNA synthesis groups. Mr. Dansky brings more than 20 years of marketing, product development, and sales experience from a variety of life science companies, including Affymetrix, Inc. (Nasdaq: AFFX) and Millipore Corporation (NYSE: MIL). Most recently, he was Vice President, Marketing, for Arcturus Bioscience where he led the commercialization of microgenomics products for life science research and clinical diagnostics markets.
Laura C. Lauman, Mark Stevenson, and Michael G. Schneider assumed leadership of their divisions after they were created in July 2004. Like Mr. Murray, each is responsible for defining and executing strategic direction and overall management of their division.
Ms. Lauman has held progressively more responsible positions managing Applied Biosystems mass spectrometry-related product lines since joining the company in 1988. In addition to her role as Division President, Proteomics and Small Molecules, she is responsible for the management and is a board member of the Applied Biosystems/MDS SCIEX Joint Venture.
Prior to his current position, Mr. Stevenson was President and General Manager of Applied Biosystems Japan Ltd, responsible for directing the sales, service and support efforts in Japan. Previously, Mr. Stevenson had similar responsibility for Applied Biosystems' genomics and informatics business throughout Europe. He joined Applied Biosystems in 1998. His Applied Markets division produces reagent kits for human identification and market opportunities in biosecurity, food/agriculture, and environment.
Mr. Schneider joined Applied Biosystems in 2004 as Vice President, Worldwide Service. His career spans more than 20 years at Eastman Kodak, and included service as Director of Operations and Service Strategy and Director of Worldwide Service Operations for the Health Imaging Division. At Kodak, Mr. Schneider was responsible for creating and implementing worldwide service strategies to enhance the company's overall service offerings. He has similar responsibilities at Applied Biosystems.
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2004. The Celera Genomics Group (NYSE:CRA) is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. It is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/.
--30--WG/sf*
CONTACT: Applied Biosystems Ana Kapor, 650-638-6227 (Media) ana.kapor@appliedbiosystems.com Linda Greub, 650-554-2349 (Investors) linda.greub@appliedbiosystems.com David Speechly, Ph.D., (+) 44-162-273-9150 (European Media and Investors) speechdp@eur.appliedbiosystems.com
KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY MANAGEMENT CHANGES SOURCE: Applied Biosystems
Copyright Business Wire 2005
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Applera Corp. - Applied Biosystemsmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Applera Corp. - Applied Biosystemsmehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.